Protara Therapeutics
TARA
41 hedge funds and large institutions have $69.3M invested in Protara Therapeutics in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 19 reducing their positions, and 17 closing their positions.
1,788% more call options, than puts
Call options by funds: $151K | Put options by funds: $8K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
12.61% less ownership
Funds ownership: 75.94% → 63.33% (-13%)
16% less funds holding
Funds holding: 49 → 41 (-8)
47% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 17
48% less capital invested
Capital invested by funds: $134M → $69.3M (-$64.7M)
58% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 19
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$1.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.14M |
| 3 |
Millennium Management
New York
|
+$784K |
| 4 |
Two Sigma Investments
New York
|
+$628K |
| 5 |
Morgan Stanley
New York
|
+$538K |
Top Sellers
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$5.98M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.51M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.03M |
| 4 |
MS
Maven Securities
St Helier,
Jersey
|
-$2.51M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.72M |
TARA Hedge Fund Activity: Q2 2021 in Review
41 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q2 2021, worth a combined $69.3M — down 48% from $134M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of TARA and 9 opened new positions — a net loss of 8 holders — while 19 trimmed existing stakes and 8 added.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $1.5M. The largest seller was Artisan Partners, exiting entirely with an estimated $5.98M sold.
- 41 institutional investors held Protara Therapeutics (TARA) as of Q2 2021, down from 49 in Q1 2021.
- Funds reported $69.3M of Protara Therapeutics stock for Q2 2021, down 48% quarter-over-quarter.
- 9 funds opened new Protara Therapeutics positions in Q2 2021 and 17 closed out, a net change of -8 holders.
- The largest Protara Therapeutics buyer in Q2 2021 was Goldman Sachs, an estimated $1.5M added.
- The largest Protara Therapeutics seller in Q2 2021 was Artisan Partners, an estimated $5.98M sold.
Based on aggregated 13F filings for Q2 2021.